Coherus Biosciences, INC 10-Q quarterly reports

Coherus Oncology's Q2 2026 Form 10-Q reveals continued operational losses and a significant decrease in cash reserves, though LOQTORZI sales show growth.

Coherus Oncology, Inc. reported first quarter 2026 results, with net revenue from continuing operations increasing to $12.3 million, driven by LOQTORZI sales growth.

Coherus Oncology reports Q3 2025 results, highlighting LOQTORZI revenue growth and the completion of its biosimilar divestiture strategy, alongside ongoing operating losses.

Coherus Oncology, Inc. reported a significant net income driven by the divestiture of its biosimilar businesses, while continuing to advance its immuno-oncology pipeline and commercialize LOQTORZI.

Coherus BioSciences announces its Q1 2025 financial results, highlighting the completion of the UDENYCA divestiture and a strategic focus on its immuno-oncology pipeline.

Coherus BioSciences reports a net income of $79.2 million for the nine months ended September 30, 2024, driven by gains from asset sales, but faces a temporary supply interruption for UDENYCA.

Coherus BioSciences reports a net income of $89.954 million for the six months ended June 30, 2024, driven by strategic asset sales and growth in UDENYCA sales, while also completing debt refinancing.

Coherus BioSciences reported a significant net income boost in Q1 2024, driven by the strategic sale of its CIMERLI ophthalmology franchise to Sandoz for $170 million, allowing the company to pay down debt and intensify its focus on its oncology portfolio.